Reduced tubular proteinuria in hypertensive rats treated with losartan is associated with higher renal cortical megalin expression

Hormone Molecular Biology and Clinical Investigation

Volumn 18, Issue 2, 2014, Pages 105-112

  Arruda Jr , Daniel F ^a   Virgulino, Stephannie G ^a   Girardi, Adriana C C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiotensin II; Cubilin; Megalin; Proteinuria; Spontaneously hypertensive rats

Indexed keywords

ALBUMIN; CREATININE; CUBILIN; DRUG VEHICLE; HYDRALAZINE; LOSARTAN; MEGALIN; ANTIHYPERTENSIVE AGENT; CELL SURFACE RECEPTOR; INTRINSIC FACTOR-COBALAMIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE URINE LEVEL; HYPERTENSION; IMMUNOBLOTTING; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; URINARY EXCRETION; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; GLOMERULAR FILTRATION BARRIER; MALE; METABOLISM; PATHOPHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; GLOMERULAR FILTRATION BARRIER; HYDRALAZINE; KIDNEY CORTEX; LOSARTAN; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2; MALE; PROTEINURIA; RATS, INBRED SHR; RECEPTORS, CELL SURFACE;

EID: 84928649013     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2013-0061     Document Type: Article

References (45)

1. Zanella MT. Microalbuminuria: cardiovascular and renal risk factors underestimated in clinical practice. Arq Bras Endocrinol Metabol 2006;50:313-21.
2. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17:2100-5.
3. Grimm RH, Jr., Svendsen KH, Kasiske B, Keane WF, Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl 1997;63:S10-4.
4. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.
5. Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003;42:936-42.
6. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-21.
7. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008;5:e207.
8. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 1998;53:1209-16.
9. Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA, McQueen M, Koon T, Yusuf S. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011;22:1353-64.
10. Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, Pittrow D, Bm M. Low-grade albuminuria and cardiovascular risk : what is the evidence? Clin Res Cardiol 2007;96:247-57.
11. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275-9.
12. Burnier M, Zanchi A. Blockade of the renin-angiotensinaldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006;24:11-25.
13. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. New Engl J Med 2004;351:1941-51.
14. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673-89.
15. Viberti G, Wheeldon NM, Microalbuminuria reduction with VSI. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8.
16. Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, DAmbrosio R, Torella R, Cozzolino D. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 2002;25:1909-13.
17. ter Wee PM, Donker AJ. Pharmacologic manipulation of glomerular function. Kidney Int 1994;45:417-24.
18. Elving LD, Wetzels JF, de Nobel E, Hoitsma AJ, Berden JH. Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy. Am J Kidney Dis 1992;20:559-63.
19. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410-5.
20. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44:874-7.
21. Oroszl M, Bieri M, Ligeti N, Farkas A, Meier B, Marti HP, Mohacsi P. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010;23:125-32.
22. Hosojima M, Sato H, Yamamoto K, Kaseda R, Soma T, Kobayashi A, Suzuki A, Kabasawa H, Takeyama A, Ikuyama K, Iino N, Nishiyama A, Thekkumkara TJ, Takeda T, Suzuki Y, Gejyo F, Saito A. Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptorand insulin-mediated signaling cross talk. Endocrinology 2009;150:871-8.
23. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T. Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertension Res 2003;26:413-9.
24. Inoue BH, Arruda-Junior DF, Campos LC, Barreto AL, Rodrigues MV, Krieger JE, Girardi AC. Progression of microalbuminuria in SHR is associated with lower expression of critical components of the apical endocytic machinery in the renal proximal tubule. Am J Physiol Renal Physiol 2013;305:F216-26.
25. Russo LM, Osicka TM, Brammar GC, Candido R, Jerums G, Comper WD. Renal processing of albumin in diabetes and hypertension in rats: possible role of TGF-beta1. Am J Nephrol 2003;23:61-70.
26. Tanaka K, Nakaki T. Reduced renal ClC-5 Cl-channel expression in spontaneously hypertensive rats with microalbuminuria. Eur J Pharmacol 2004;501:185-9.
27. Landgraf SS, Wengert M, Silva JS, Zapata-Sudo G, Sudo RT, Takiya CM, Pinheiro AA, Caruso-Neves C. Changes in angiotensin receptors expression play a pivotal role in the renal damage observed in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2011;300:F499-510.
28. Arias SC, Valente CP, Machado FG, Fanelli C, Origassa CS, de Brito T, Camara NO, Malheiros DM, Zatz R, Fujihara CK. Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydroclorothiazide association in a model of very advanced nephropathy. PLoS One 2013;8:e56215.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
31. Crajoinas RO, Lessa LM, Carraro-Lacroix LR, Davel AP, Pacheco BP, Rossoni LV, Malnic G, Girardi AC. Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHR. Am J Physiol Renal Physiol 2010;299:F872-81.
32. Gekle M. Renal tubule albumin transport. Annu Rev Physiol 2005;67:573-94.
33. Tojo A, Onozato ML, Ha H, Kurihara H, Sakai T, Goto A, Fujita T, Endou H. Reduced albumin reabsorption in the proximal tubule of early-stage diabetic rats. Histochem Cell Biol 2001;116: 269-76.
34. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340:248-55.
35. Gekle M, Knaus P, Nielsen R, Mildenberger S, Freudinger R, Wohlfarth V, Sauvant C, Christensen EI. Transforming growth factor-beta1 reduces megalin-and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003;552:471-81.
36. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int 2006;69:440-9.
37. Pollock CA, Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007;16:359-64.
38. Gekle M, Drumm K, Mildenberger S, Freudinger R, Gassner B, Silbernagl S. Inhibition of Na+-H+ exchange impairs receptormediated albumin endocytosis in renal proximal tubule-derived epithelial cells from opossum. J Physiol 1999;520:709-21.
39. Hryciw DH, Ekberg J, Pollock CA, Poronnik P. ClC-5: a chloride channel with multiple roles in renal tubular albumin uptake. Int J Biochem Cell Biol 2006;38:1036-42.
40. Marshansky V, Vinay P. Proton gradient formation in early endosomes from proximal tubules. Biochim Biophys Acta 1996;1284:171-80.
41. Gunther W, Luchow A, Cluzeaud F, Vandewalle A, Jentsch TJ. ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci U S A 1998;95:8075-80.
42. Gunther W, Piwon N, Jentsch TJ. The ClC-5 chloride channel knock-out mouse-an animal model for Dent's disease. Pflugers Arch 2003;445:456-62.
43. Piwon N, Gunther W, Schwake M, Bosl MR, Jentsch TJ. ClC-5 Cl-channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 2000;408:369-73.
44. Bakoush O, Tencer J, Torffvit O, Tenstad O, Skogvall I, Rippe B. Increased glomerular albumin permeability in old spontaneously hypertensive rats. Nephrol Dial Transplant 2004;19:1724-31.
45. Hultstrom M. Development of structural kidney damage in spontaneously hypertensive rats. J Hypertens 2012;30:1087-91.